Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, post-traumatic stress disorder (PTSD), and associated disorders.
This move positions Silo Pharma at the forefront of addressing underserved conditions in neuroscience. TBI affects millions worldwide, often leading to long-term cognitive and psychiatric impairments. Current treatment options are limited, and there is a significant unmet medical need for effective therapies. Ibogaine, a psychoactive alkaloid traditionally used in some cultures for addiction treatment, has shown potential in preclinical studies for neuroprotection and neuroplasticity, which could be beneficial for TBI recovery.
The company notes that its therapeutic focus is on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Silo’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories.
According to the press release, the patent filing is a key step in protecting Silo’s intellectual property related to ibogaine’s use in TBI and neuropsychiatric conditions. The initiative underscores the company’s commitment to advancing novel therapeutics where conventional treatments have fallen short.
For more details, the full press release can be accessed at https://ibn.fm/HdWHG. Additional information about Silo Pharma is available on their website at silopharma.com.
The implications of this announcement are significant for the biopharmaceutical industry and for patients suffering from TBI and PTSD. If successful, Silo Pharma’s ibogaine-based therapeutics could offer a new treatment paradigm, potentially improving outcomes for individuals with these debilitating conditions. The initiative also highlights the growing interest in psychedelic-derived compounds for neurological and psychiatric disorders.
